Pharmaceuticals - Haifa, Haifa District, Israel
Industry field: Drug-Device Combination product.About Neshima's LiFT Technology:Common inhalation devices (e.g. inhalers, nebulizers, etc.) are very limited in their drug delivery abilities: only small particles can be inhaled (<10 μm) and inhalable doses remain low. These drawbacks are associated with poor treatment outcomes and an ongoing lack of treatment for critical lung conditions.NESHIMA's liquid foam therapy (LiFT) technology overcomes these challenges by using foam as a carrier for the delivery of therapeutics to the lungs. Such an approach represents a paradigm shift in the field of pulmonary drug delivery. LiFT distributes homogeneously throughout the lungs, and compared to nebulizers LiFT can deliver drugs ~X100 times faster, more than X10 larger particles, and at much higher efficiencies.LiFT opens a broad range of new treatment opportunities. Some examples include surfactant replacement therapy in ARDS (including for severe COVID-19 patients) where large doses are required; and direct delivery of stem cells into the lungs, which are too large to be inhaled, for treatment of ARDS (including COVID-19), COPD, and IPF.For more details, please contact: Dr. Yan OstrovskiCo-Founder & CEO, Neshima Medical Ltd yanost@gmail.com
Outlook
Nginx
WordPress.org
Mobile Friendly
Google Cloud Hosting